Global Post-operative Pain Therapeutics Market - 2022-2029

Global Post-operative Pain Therapeutics Market - 2022-2029

Market Overview

Post-Operative Pain Therapeutics Market size was valued at US$ xx million in 2021 and is estimated to reach US$ XX million by 2029, growing at a CAGR of x% during the forecast period (2022-2029).

Postsurgical or postoperative pain is long-lasting after surgery; it is nearly 3 to 6 months. The pain varies from patient to patient as well as quality and location from the pain experienced before the surgery, and it is usually related to iatrogenic neuropathic pain caused by surgical injury to a crucial peripheral nerve. While most all surgeries can lead to postoperative pain, some surgeries have a high risk of causing nerve damage, such as breast and thoracic surgery, leg amputation, inguinal hernia repair, and coronary artery bypass surgery. To reduce this pain, various medications are used, such as NSAIDs.

Market Dynamics

The post-operative pain therapeutics market growth is driven by the rise in the number of surgeries, launching of new drugs in the market and research and development activities, rising geriatric population in developing countries, growing prevalence of acute diseases, and increasing patient awareness related to surgeries and operations.

The rising number of surgeries is expected to drive the market growth

The rising number of different surgeries, such as cancer and eye, is expected to boost the market over the forecast period. As per the American Society of Plastic Surgeons 2020 data report, nearly 15.6 million cosmetic procedures were performed in 2020, of which 2.3 million were cosmetic surgical procedures and 13.2 million cosmetic minimally-invasive procedures. Furthermore, females have a higher number of cosmetic surgeries than males, with females performing approximately 92% of all cosmetic procedures and males performing approximately 8% of all cosmetic procedures in 2020. Furthermore, among the children who are in the 13–19 age group, only 2% of the total contributed to the surgeries. Some of the most common procedures for teens include eyelid surgery, nose reshaping, ear surgery, laser hair removal, and laser skin resurfacing. The healthcare professional recommended the NSAID drugs to reduce the pain of this after cosmetic surgery.

Moreover, according to the article published in the South African Journal of Physiology, osteoarthritis has an occurrence and progression rate of 22% at 40 years of age. At the more advanced stage of disease progression and when limited management fails to provide the individual with effective pain relief, then joint replacement surgery is recommended by the health care professional. The increase in surgeries simultaneously increases the demand for post-operative therapeutics worldwide.

The side effects of post-operative pain therapeutics will hamper the growth of the market

However, all drugs have side effects, for instance, all opioids have their side effects which is limiting their use. The major side effect related to the use of opioids is respiratory depression. The rising cases of a drug overdose and side effects associated with postoperative pain drugs are limits to the overall market growth.

COVID-19 Impact Analysis

The appearance of COVID-19 considerably impacted the global post-operative pain therapeutics market. In March 2020, the United States president announced a national health emergency that resulted in a shutdown of all less necessary activities throughout the country. The American College of Surgeons (ACS) and other major surgical specialty societies declared that they would be minimizing, postponing, or canceling elective surgical procedures in mid-March and published guidelines for triage of elective surgical procedures by surgical specialty. The Centers for Medicare & Medicaid Services (CMS) and the US Surgeon General also published statements and gave suggestions for the postponement of unnecessary surgical procedures. In addition, in February 2022, as per the article published in Frontiers in Surgery the number of operations in surgical clinics was reduced because of the postponement of selective operations during the pandemic period. The drop in the number of surgeries indicates a serious rise in the workload on surgical clinics and hospitals in the post-pandemic period.

Furthermore, due to pandemic concerns, delays in diagnosis, especially in tumors of typical interest such as breast cancer, result in further advanced-stage tumors and disease progression. Moreover, the number of surgeries for breast cancer, especially upfront surgeries, dropped by around 50–60% in the first wave of the pandemic period. As the situation is recovering from the pandemic, more hospitals are regularly giving the proper treatment and they are performing surgeries on the patients, which is boosting the postoperative pain market worldwide.

Segment Analysis

The NSAIDs segment is expected to grow at the fastest CAGR during the forecast period (2022-2029)

The NSAIDs segment is expected to boost the market over the period of the forecast. NSAIDs are a broad-ranging class of drugs with multiple characteristics such as cyclo-oxygenase (COX)-1 or COX-2 selectivity, targeted action, and analgesic potency. In March 2022, as per the article published in Pharmacological Management of Postoperative Pain, the clinical guidelines to manage postoperative pain were issued by the American Pain Society, the American Society of Regional Anesthesia and Pain Medicine, and the American Society of Anesthesiologists’ Committee on Regional Anesthesia, outlined a strong suggestion based on high-quality evidence that physicians or clinicians provide adult and paediatric patients with paracetamol or acetaminophen (APAP) or nonsteroidal anti-inflammatory drugs (NSAIDs) as part of a multimodal analgesic regimen to handle the postoperative pain unless there are any specific contraindications. NSAIDs can have potent central effects similar to those of opioids. In addition, the quick onset of analgesic activity is a key prescribing consideration for treating acute postoperative pain. For instance, the study analysing and validating the rate of onset of a variety of NSAIDs in dental pain found that dexketoprofen 25 mg was so much faster (30 minutes) than diclofenac 50 mg (60 minutes), tramadol 100 mg (120 minutes), and piroxicam 20 mg (120 minutes). Because of its rapid onset of action, there is an increasing demand for NSAIDs in the market to treat postoperative pain.

Geographical Analysis

North America region holds the largest market share of the global post-operative pain therapeutics market

North America dominates the market for post-operative pain therapeutics and is expected to show a similar trend over the forecast period. It is estimated to hold a significant market size over the forecast period (2022-2029) owing to increasing number of surgeries, advanced healthcare systems, easily availability of therapeutics for treatment. The launching new drugs development, research activity and approval of various drugs drive the market in the North American region. For instance, in March 2022, Virpax Pharmaceuticals, Inc. is completed all FDA-required pre-clinical studies for Epoladerm Virpax’s investigational pre-filled topical spray analgesic product to manage chronic pain associated with osteoarthritis (OA) of the knee. The key Investigational New Drug Application (IND) allows studies to be completed, on irritation, dermal toxicity phototoxicity and pharmacokinetic characteristics.

Furthermore, in June 2022, Heron Therapeutics, Inc. announced the online publication of a new study evaluating the efficacy and safety of ZYNRELEF (bupivacaine and meloxicam) extended-release solution as the foundation of a perioperative non-opioid multimodal analgesic (MMA) regimen in patients undergoing total knee arthroplasty (TKA). The ZYNRELEF is approved by the U.S. Food and Drug Administration (FDA) for use in adults for soft tissue or peri-articular instillation to produce postsurgical analgesia for up to 72 hours after foot and ankle, small-to-medium open abdominal, and lower extremity total joint arthroplasty surgical procedures.

Competitive Landscape

The Post-operative Pain Therapeutics market is a moderately competitive presence of local as well as global companies. Some of the key players which are contributing to the growth of the market are Mallinckrodt Pharmaceuticals, Trevena Inc., Heron Therapeutics, Teva Pharmaceutical Industries Ltd., Camarus, Bayer AG, Pacira BioSciences Inc., Pfizer Inc., Novartis AG, Hyloris Pharmaceuticals SA, and Eli Lilly & Company among others. The major players are adopting several growth strategies such as Treatment type launches, acquisitions, and collaborations, which are contributing to the growth of the post-operative pain therapeutics market globally.

For instance,

• In November 2021, Antibe Therapeutics Inc. is pleased to provide additional detail on otenaproxesul’s development plan for acute pain indications. Further, this drugs can used for post-operative pain, as a safe non-opioid analgesic.

Hyloris Pharmaceuticals SA

Overview:

Hyloris is a biopharma company involved in innovating, reinventing, and optimizing existing medications to direct important healthcare necessities and deliver related improvements for patients, healthcare professionals and payors. Hyloris has a patented portfolio of 13 repurposed and reformulated modernized medicines that have the potential to provide remarkable advantages over other alternatives.

Treatment type Portfolio:

Maxigesic IV: Maxigesic IV is a novel, patented; non-opioid used for treatment of post-operative pain and is a distinctive combination of 1000 mg paracetamol and 300 mg ibuprofen solution for infusion. It is currently licensed in more than 100 countries across the world, and registered in 24 countries. It is now available in 5 countries including Australia, New Zealand, The United Arab Emirates, Germany, and Austria.

The global post-operative pain therapeutics market report would provide access to approximately 70+ market data tables, 65+ figures, and in the range of 250+ (approximate) pages.